Project Home Project Link 1 Link 2 Link 3 Progress Link 1 Link 2 Link 3 Health and Safety Link 1 Link 2 Link 3 Human Practise Link 1 Link 2 Link 3 Team Link 1 Link 2 Link 3 Cardiff 2017 Project Brief Creating a thyroid stimulating hormone antagonist by removing essential N-linked glycosylation groups The objective of this project was to take the native version of thyroid stimulating hormone (TSH, AKA. Thyrotropin) which activates a cascade in the thyroid gland to produce thyroid hormones thyroxine (T4) and tri-iodotyrosine (T3). By changing the amino acid sequence of the native TSH protein, we can disable the gland-activating effects of TSH, whilst still allowing TSH to bind to the gland. The engineered version still binds to the thyroid gland but does not activate it. Thus, it competitively inhibits the native TSH, and is potentially a therapeutic treatment for hyperthyroidism.
The objective of this project was to take the native version of thyroid stimulating hormone (TSH, AKA. Thyrotropin) which activates a cascade in the thyroid gland to produce thyroid hormones thyroxine (T4) and tri-iodotyrosine (T3).
By changing the amino acid sequence of the native TSH protein, we can disable the gland-activating effects of TSH, whilst still allowing TSH to bind to the gland. The engineered version still binds to the thyroid gland but does not activate it. Thus, it competitively inhibits the native TSH, and is potentially a therapeutic treatment for hyperthyroidism.
